Thrombin generation and coagulation factor activities: Evaluation and comparison with the international normalized ratio

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 5, 2009, Pages 358-365

  Christensen, Thomas D ^a   Jensen, Claus ^b   Larsen, Torben B ^c   Christiansen, Kirsten ^a   SØrensen, Benny ^a,d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNI C   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Coagulation factors; Coumarins; International normalized ratio; Oral anticoagulant; Thrombin generation

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 9; PROTHROMBIN; THROMBIN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CALIBRATION; DRUG MONITORING; FACTOR IX; FACTOR VII; FACTOR X; FEMALE; HEART VALVE PROSTHESIS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROTHROMBIN; SENSITIVITY AND SPECIFICITY; THROMBIN; THROMBOPHILIA; WARFARIN;

EID: 68149131599     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832aa68c     Document Type: Article

References (21)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest 2008; 133:160S-198S.
2. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367:404-411.
3. Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation 2001; 104:2311-2317.
4. D'Angelo A, Della Valle P, Crippa L, Fattorini A, Pattarini E, Vigano DS. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. Haematologica 2002; 87:1074-1080.
5. Gatt A, van Veen JJ, Bowyer A, Woolley AM, Cooper P, Kitchen S, et al. Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic international normalized ratio is not due to inflammation. Br J Haematol 2008; 142:946-952.
6. Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84:747-751.
7. Gatt A, van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008; 100: 350-355.
8. Hemker HC, Al DR, De SE, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96:553-561.
9. Sarode R, Rawal A, Lee R, Shen YM, Frenkel EP. Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy. Br J Haematol 2006; 132:604-607.
10. Costa IM, Soares PJ, Afonso M, Ratado P, Lanaot JM, Falcāo AC. Therapeutic monitoring of warfarin: the appropriate response marker. J Pharm Pharmacol 2000; 52:1405-1410.
11. Van Geest-Daalderop JH, Hutten BA, Péquériaux NC, Haas FJ, Levi M, Sturk A. The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: consequences for the assessment of the dose. Thromb Haemost 2007; 98:738-746.
12. Watala C, Golanski J, Kardas P. Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients. Thromb J 2003; 1:7.
13. Paul B, Oxley A, Brigham K, Cox T, Hamilton PJ. Factor II, VII, IX and X concentrations in patients receiving long term warfarin. J Clin Pathol 1987; 40:94-98.
14. Lind SE, Callas PW, Golden EA, Joyner KA Jr, Ortel TL. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 1997; 8:48-53.
15. Bruns DE, Huth EJ, Magid E, Young DS. Toward a checklist for reporting of studies of diagnostic accuracy of medical tests. Clin Chem 2000; 46:893-895.
16. Van den Besselaar AM, Barrowcliffe TW, Houbouyan-Réveillard LL, Jespersen J, Johnston M, Poller L, et al. Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost 2004; 2:1946-1953.
17. Braun S, Watzke H, Hasenkam JM, Schwab M, Wolf T, Dovifat C, et al. Performance evaluation of the new CoaguChek XS system compared with the established CoaguChek system by patients experienced in INR-self management. Thromb Haemost 2007; 97:310-314.
18. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70:617-624.
19. Poller L, Keown M, Ibrahim SA, van der Meer FJ, Van den Besselaar AM, Tripodi A, et al. Quality assessment of CoaguChek point-of-care prothrombin time monitors: comparison of the European community-approved procedure and conventional external quality assessment. Clin Chem 2006; 52:1843-1847.
20. Christensen TD. Self-management of oral anticoagulant therapy: a review. J Thromb Thrombolysis 2004; 18:127-143.
21. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103:2630-2635.